Publications by authors named "Shu'an Jin"
Article Synopsis
- A study evaluated a new long-lasting pain relief medication called QP001, compared to a placebo, to determine its effectiveness and safety for patients after abdominal surgery.
- Conducted across 23 centers, 255 patients were administered either QP001 or placebo, and the results showed QP001 significantly reduced pain intensity for up to 24 hours post-surgery.
- The trial indicated that QP001 also reduced the need for morphine and increased patient satisfaction, with no significant difference in adverse events compared to placebo.
Study Objective: HR18034, composed of the ropivacaine encapsulated in multi-lamellar, concentric circular structure liposomes as the major component and a small amount of free ropivacaine, has performed well in animal experiments and phase I clinical trials. This trial was to investigate the efficacy, safety, pharmacokinetic profile and the minimum effective dose of HR18034 for postoperative analgesia after hemorrhoidectomy compared with ropivacaine.
Design: A multicenter, randomized, double-blind trial.
Background: Preliminary clinical trials of adamgammadex, a new cyclodextrin-based selective reversal agent, have demonstrated its efficacy in reversing neuromuscular block by rocuronium.
Methods: This multicentre, randomised, double-blind, positive-controlled, non-inferiority phase III clinical trial compared the efficacy and safety of adamgammadex and sugammadex. We randomised 310 subjects to receive adamgammadex (4 mg kg) or sugammadex (2 mg kg) at reappearance of the second twitch of the train-of-four (TOF), and standard safety data were collected.